Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359239 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
A Phase 1 study, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03359239 is a Phase 1 study that has completed, run by Matthew Galsky. The registered enrollment target is 10 participants.
The verdict
NCT03359239, a Phase 1 study, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that has spread to other organs.
Interventions
- DRUG Atezolizumab
- DRUG Normal saline
- DRUG Poly ICLC
- BIOLOGICAL PGV001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03359239
The ClinicalTrials.gov registry entry for NCT03359239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Atezolizumab is the first listed.
NCT03359239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03359239 about?
NCT03359239 is a clinical study titled "Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer". The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that...
What is the current status of trial NCT03359239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-05-08. Estimated completion is 2021-10-12.
What interventions are being tested in trial NCT03359239?
The interventions under investigation include: Atezolizumab (DRUG), Normal saline (DRUG), Poly ICLC (DRUG), PGV001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03359239?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.